For pure weight-loss endpoints, retatrutide outperforms semaglutide by roughly 9 percentage points at peak dose: 24.2% versus ~15% mean body-weight loss at comparable durations [3][4]
Microdosing or starting with a l ower dose may help to prevent gastrointestinal side effects
Boxed warning context
its relevance to retatrutide specifically is not yet established A history of pancreatitis or significant gastrointestinal disease Gallbladder disease , including a history of gallstones or cholecystitis Diabetes mellitus , particularly if managed with insulin or sulphonylureas, due to hypoglycaemia risk Cardiovascular disease , including arrhythmias or recent cardiac events Renal or hepatic impairment , which may affect tolerability and increase the risk of dehydration-related complications Pregnancy or breastfeeding no safety data exist for retatrutide in these groups Use of oral medicines where absorption may be affected by delayed gastric emptying , such as levothyroxine or combined oral contraceptives Seek urgent medical attention if you experience severe or persistent nausea or vomiting, persistent abdominal pain (which may indicate pancreatitis or gallbladder disease), signs of an allergic reaction (rash, swelling, difficulty breathing), chest pain, palpitations, or signs of dehydration
KFF maintains full editorial control over all of its policy analysis, polling, and journalism activities.
